CliffBio
small molecule

STIOLTO RESPIMAT

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Loss of exclusivityOctober 2030latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand nameSTIOLTO RESPIMAT
Active ingredientOLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
StrengthEQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH
Dosage formSPRAY, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalMay 2015
Marketing statusRX

Listed patents

PatentExpiresType
8733341October 2030product
7837235*PEDSeptember 2028—
7837235March 2028product
7396341*PEDApril 2027—
9027967March 2027product
7727984January 2027substance
7396341October 2026product

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

STIOLTO RESPIMAT patent cliff — loss of exclusivity October 2030 | CliffBio